Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARNET: Dostarlimab in Advanced Solid Tumors
NCT02715284Phase 1Active, not recruiting
- Start
- Mar 2016
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 13
01
Overview
Phase 1, open-label trial of dostarlimab in solid tumor, endometrial cancer (EC), non-small cell lung cancer (NSCLC) and 3 more (7 arms). Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Objective Response Rate at 2 years and 1 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
solid tumorendometrial cancer (EC)non-small cell lung cancer (NSCLC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02715284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715284.